AstraZeneca has asked Health Canada to review a new long-acting antibody combination that could be used to prevent symptomatic COVID-19.
If approved, it would be the first antibody protection of its kind in Canada.
Read more:
AstraZeneca COVID-19 drug prevents severe disease if given early, company says
The company says its clinical trials showed the antibody treatment was well tolerated and reduced the risk of developing symptomatic COVID-19 by 77 per cent compared to a placebo.
AstraZeneca Canada says it could be a good option for vulnerable populations who aren’t able to develop a strong protective response from a vaccine.
The company says preliminary findings show the antibodies neutralize recent COVID-19 variants, including the Delta and Mu variants.
Health Canada has said all COVID-19 vaccine and drug submissions will be prioritized and reviewed on an expedited timeline.
Read more:
AstraZeneca seeks U.S. emergency approval for COVID-19 prevention drug
© 2021 The Canadian Press
For all the latest Health News Click Here
For the latest news and updates, follow us on Google News.
